1. Muller, N, de la Roche, M, **de la Roche M**. Insights from the bottom-up development of LGR5-targeting immunotherapeutics. *Immunotherapy Advances*, 5(1), 2025.
2. Sur I, Zhao W, Zhang J, Kling Pilström M, Webb AT, Cheng H, Ristimäki A, Katajisto P, Enge M, Rannikmae H, **de la Roche M**, Taipale J. Shared requirement for MYC upstream super-enhancer region in tissue regeneration and cancer. *Life Sci Alliance*. 2025 8(6):e202403090.
3. Chen H-C, Mueller N, Stott K, Rivers E… **de la Roche M**. Novel immunotherapeutics against LGR5 to target multiple cancer types. *EMBO Mol Med:* 2024.
4. Hanna J, Beke F, O'Brien LM, Kapeni C, Chen HC, Carbonaro V, Kim AB, Kishore K, Adolph TE, Skjoedt MO, Skjoedt K, **de la Roche M.** de la Roche M**.** Cell-autonomous Hedgehog signaling controls Th17 polarization and pathogenicity. *Nat. Comms* 2022.
5. Tovey CA, Tsuji C, Egerton A, Bernard F, Guichet A, **de la Roche M**, Conduit PT. Autoinhibition of Cnn binding to g-TuRCs prevents ectopic microtubule nucleation and cell division defects. J Cell Biol. 2021.
6. Diamante A, Chaturbedy PK, Rowling PJE, Kumita JR, Eapen RS, McLaughlin SH, **de la Roche M**, Perez-Riba A, Itzhaki LS. Engineering mono- and multi-valent inhibitors on a molecular scaffold. *Chem. Sci.* 2021.
7. Rannikmae, H., Peel, S., Barry, S., Senda, T, **de la Roche, M.** Mutational inactivation of Apc in the intestinal epithelia compromises cellular organisation. *J. Cell Sci.* 2021.
8. Farooqi, AA, **de la Roche, M,** Djamgoz, MBA and Siddik, ZH. Overview of the oncogenic signalling pathways in colorectal cancer: Mechanistic Insights. *Semin Cancer Biol*. 2019.
9. Urbischek, M, Rannikmae, H, Foets, T, Ravn, K, Hyvonen, M, **de la Roche, M.** Organoid culture media containing growth factors of defined cellular activity. *Scientific Reports*. 2019.
10. Xu W, Lau YH, Fischer G, Tan YS, Chattopadhyay A, **de la Roche M**, Hyvönen M, Verma C, Spring DR, Itzhaki LS. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase. J Am Chem Soc. 2017.
11. de la Roche, M*, Ibrahim, AE, Mieszczanek, J, and Bienz, M*****. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. *Cancer Res.* 74(5):1495-1505. **Corresponding authors.* 2014.
12. Yang Y, **de la Roche M,** Crawley SW, Li Z, Furmaniak-Kazmierczak E and Cote GP. PakB binds to the SH3 domain of Dictyostelium Abp1 and regulates its effects on cell polarity and early development. *Mol Biol Cell.* 2013.
13. de la Roche, M, Rutherford, T, Gupta, D, Veprintsev, DB, Saxty, B, Freund, SM and Bienz, M. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. *Nature Comms.* 2012.
14. de la Roche, M, Tessier, S and Storey, K. Structural and functional properties of glycerol-3-phosphate dehydrogenase from a mammalian hibernator. *Protein J.* 2012.
15. Metcalfe, C, Ibrahim, A, Graeb, M, **de la Roche, M**, Fiedler, M, Schwarz-Romond, T, Winton, D, Corfield, A. and Bienz, M. Dvl2 promotes *Apc*-driven intestinal neoplasia and intestinal crypt-cell growth through mTOR signalling. *Cancer Res.* 2010.
16. Mieszczanek, J, **de la Roche, M** and Bienz, M. A role of Pygopus as an anti-repressor in facilitating Wnt-dependent transcription. *Proc Natl Acad Sci U S A.* 2008.
17. de la Roche, M, Worm, J, and Bienz, M. The function of BCL9 in Wnt/β-catenin signalling and colorectal cancer cells, *BMC Cancer.* 2008.
18. de la Roche, M and Bienz, M. Wingless-independent association of Pygopus with dTCF target genes. *Curr Biol.* 2007.